Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Protalix BioTherapeutics Company Profile (NYSE:PLX)

Consensus Ratings for Protalix BioTherapeutics (NYSE:PLX) (?)
Ratings Breakdown: 1 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $5.17 (160.94% upside)

Analysts' Ratings History for Protalix BioTherapeutics (NYSE:PLX)
Show:
DateFirmActionRatingPrice TargetDetailsShare
11/12/2014R. F. LaffertyLower Price TargetBuy$8.00 -> $5.00ViewTweet This Rating  Share This Rating on StockTwits
8/11/2014Jefferies GroupReiterated RatingHold$4.25 -> $3.50ViewTweet This Rating  Share This Rating on StockTwits
5/13/2014JPMorgan Chase & Co.Lower Price TargetOverweight$8.00 -> $7.00ViewTweet This Rating  Share This Rating on StockTwits
5/12/2014Jefferies GroupReiterated RatingHold$5.50 -> $4.25ViewTweet This Rating  Share This Rating on StockTwits
1/24/2014R. F. LaffertyInitiated CoverageBuy$8.00ViewTweet This Rating  Share This Rating on StockTwits
1/14/2014Jefferies GroupBoost Price Target$5.00 -> $5.50ViewTweet This Rating  Share This Rating on StockTwits
10/21/2013JPMorgan Chase & Co.Initiated CoverageOverweightViewTweet This Rating  Share This Rating on StockTwits
3/19/2013OppenheimerReiterated RatingOutperform$7.00ViewTweet This Rating  Share This Rating on StockTwits
(Data available from 12/18/2012 forward)